174.17
Natera Inc stock is traded at $174.17, with a volume of 1.14M.
It is up +2.89% in the last 24 hours and up +3.36% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$169.27
Open:
$170
24h Volume:
1.14M
Relative Volume:
0.91
Market Cap:
$23.90B
Revenue:
$1.96B
Net Income/Loss:
$-253.24M
P/E Ratio:
-91.61
EPS:
-1.9012
Net Cash Flow:
$94.06M
1W Performance:
+2.22%
1M Performance:
+3.36%
6M Performance:
+17.65%
1Y Performance:
+33.92%
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NTRA
Natera Inc
|
174.17 | 23.23B | 1.96B | -253.24M | 94.06M | -1.9012 |
![]()
TMO
Thermo Fisher Scientific Inc
|
524.58 | 198.17B | 43.21B | 6.58B | 6.17B | 17.28 |
![]()
DHR
Danaher Corp
|
205.14 | 144.97B | 24.01B | 3.41B | 4.86B | 4.7082 |
![]()
IDXX
Idexx Laboratories Inc
|
633.32 | 49.29B | 4.04B | 985.66M | 774.34M | 12.01 |
![]()
A
Agilent Technologies Inc
|
138.23 | 38.73B | 6.79B | 1.22B | 1.09B | 4.2644 |
![]()
IQV
Iqvia Holdings Inc
|
203.77 | 33.69B | 15.70B | 1.24B | 2.01B | 6.9036 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
Jan-23-25 | Initiated | Barclays | Overweight |
Jun-03-24 | Resumed | Jefferies | Buy |
Apr-08-24 | Resumed | Craig Hallum | Buy |
Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
Dec-29-23 | Reiterated | BTIG Research | Buy |
Dec-14-23 | Initiated | Guggenheim | Buy |
Dec-13-23 | Initiated | Wolfe Research | Outperform |
Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
Sep-28-23 | Initiated | Bernstein | Mkt Perform |
Jul-05-23 | Resumed | JP Morgan | Overweight |
May-05-23 | Initiated | UBS | Buy |
Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Aug-25-22 | Initiated | Credit Suisse | Outperform |
Apr-25-22 | Initiated | Stephens | Overweight |
Mar-08-22 | Initiated | Goldman | Buy |
Jan-06-22 | Resumed | Piper Sandler | Overweight |
Oct-15-21 | Resumed | Cowen | Outperform |
Jun-15-21 | Initiated | Raymond James | Mkt Perform |
May-25-21 | Initiated | Wells Fargo | Overweight |
Jan-28-21 | Initiated | Truist | Buy |
Oct-08-20 | Initiated | BTIG Research | Buy |
Sep-28-20 | Initiated | Morgan Stanley | Overweight |
Sep-17-20 | Initiated | SVB Leerink | Outperform |
Jun-10-20 | Resumed | Piper Sandler | Overweight |
May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-05-18 | Initiated | JP Morgan | Neutral |
Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
Nov-10-16 | Reiterated | The Benchmark Company | Buy |
May-23-16 | Reiterated | The Benchmark Company | Buy |
May-11-16 | Reiterated | The Benchmark Company | Buy |
Apr-19-16 | Initiated | The Benchmark Company | Buy |
Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Aug-04-15 | Initiated | Robert W. Baird | Outperform |
Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
Jul-27-15 | Initiated | Piper Jaffray | Overweight |
Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
The Bull Case For Natera (NTRA) Could Change Following Breakthrough Study Results for Signatera Platform - Yahoo Finance
Phase 3 IMvigor011 results: Natera to discuss ESMO data on Oct. 23 investor call with lead PI - Stock Titan
Natera (NTRA) Valuation: Exploring Upside as Investors Weigh Recent Performance and Long-Term Potential - Yahoo Finance
Why Natera Inc. stock remains on buy listsJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium - BioSpace
Natera says to present 14 studies at Esmo, including Imvigor011 oral presentation - MarketScreener
Natera Says To Present 14 Studies At ESMO, Including Imvigor011 Oral Presentation - TradingView
Legal Advantage Investments Inc. Invests $591,000 in Natera, Inc. $NTRA - MarketBeat
waypoint wealth counsel Makes New Investment in Natera, Inc. $NTRA - MarketBeat
NeoGenomics rallies after court win in Natera patent dispute - MSN
Can volume confirm reversal in Natera Inc.Entry Point & Fast Moving Market Watchlists - newser.com
Natera's (NTRA) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Natera, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Natera, Inc. Forms Golden Cross, Signaling Potential Bullish Breakout Ahead - Markets Mojo
Natera, Inc. $NTRA Position Increased by Narwhal Capital Management - MarketBeat
QRG Capital Management Inc. Increases Position in Natera, Inc. $NTRA - MarketBeat
Natera Inc Stock Analysis and ForecastTrading Volume Surges & Compound Your Gains With Quality Stocks - earlytimes.in
Truist Financial Corp Purchases 4,525 Shares of Natera, Inc. $NTRA - MarketBeat
What drives Natera Inc stock priceDividend Yield Trends & Low Cost Portfolio Ideas - earlytimes.in
Chart based exit strategy for Natera Inc.2025 Market WrapUp & Safe Capital Growth Tips - newser.com
Is Natera Inc. building a consolidation base2025 Stock Rankings & Precise Swing Trade Entry Alerts - newser.com
Mirae Asset Global Investments Co. Ltd. Purchases 2,837 Shares of Natera, Inc. $NTRA - MarketBeat
How institutional ownership impacts Natera Inc. stockJuly 2025 Technicals & Fast Exit Strategy with Risk Control - newser.com
Natera's Enrollment Surge in EXPAND Trial Could Be a Game Changer for Natera (NTRA) - simplywall.st
Combining machine learning predictions for Natera Inc.Market Weekly Review & Weekly Chart Analysis and Trade Guides - newser.com
Natera, Inc. $NTRA Shares Purchased by ASR Vermogensbeheer N.V. - MarketBeat
Barclays Keeps Their Buy Rating on Natera (NTRA) - The Globe and Mail
Natera (NTRA): Exploring Valuation as Share Price Pulls Back Despite Strong Growth - simplywall.st
Natera (NTRA): Assessing Valuation Potential as Shares Enter a Quiet Phase - simplywall.st
Is Natera Inc. a candidate for recovery play2025 AllTime Highs & Accurate Trade Setup Notifications - newser.com
Natera Stock (NTRA) Opinions on EXPAND Trial Enrollment and Insider Sales - Quiver Quantitative
Natera (NASDAQ:NTRA) Insider Sells $479,970.00 in Stock - MarketBeat
Natera CEO Chapman sells $3.7m in stock By Investing.com - Investing.com Australia
Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT - BioSpace
Natera enrolls over 1,600 patients in EXPAND trial for fetal testing - Investing.com Nigeria
Natera (NASDAQ:NTRA) CFO Sells $403,666.55 in Stock - MarketBeat
Insider Sell: Solomon Moshkevich Sells 3,000 Shares of Natera In - GuruFocus
Natera (NTRA) sec. Rabinowitz sells $221k in shares By Investing.com - Investing.com Australia
Natera CFO Brophy sells $403,673 in shares By Investing.com - Investing.com South Africa
Natera CEO Chapman sells $3.7m in stock - Investing.com India
Natera (NTRA) sec. Rabinowitz sells $221k in shares - Investing.com India
Natera CFO Brophy sells $403,673 in shares - Investing.com India
Natera Inc: president Moshkevich sells $479k in stock By Investing.com - Investing.com South Africa
Natera Inc: president Moshkevich sells $479k in stock - Investing.com India
Natera, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Why Natera’s Stock is Gaining Attention - TipRanks
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Natera Inc Stock (NTRA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER |
Sep 30 '25 |
Sale |
162.05 |
1,364 |
221,040 |
203,300 |
Chapman Steven Leonard | CEO AND PRESIDENT |
Oct 01 '25 |
Sale |
160.00 |
14,083 |
2,253,233 |
154,072 |
Chapman Steven Leonard | CEO AND PRESIDENT |
Sep 30 '25 |
Sale |
162.05 |
9,109 |
1,476,139 |
168,155 |
Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
Sep 30 '25 |
Sale |
162.05 |
2,491 |
403,674 |
69,189 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):